{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:05:39Z","timestamp":1781557539053,"version":"3.54.5"},"reference-count":41,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This is a post hoc analysis of patients with T2D aged less than 65\u2009years and those aged 65\u2009years or older who participated in randomized, double\u2010blind, phase III studies of ertugliflozin. Efficacy was evaluated in a pooled analysis of three placebo\u2010controlled studies (ertugliflozin monotherapy and add\u2010on therapy). Safety was evaluated in a pooled analysis of seven placebo\u2010 and active\u2010controlled studies (including those used for efficacy). Least\u2010squares mean change from baseline was calculated for HbA1c, fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In participants aged less than 65\u2009years, the placebo\u2010adjusted mean changes from baseline in HbA1c, BW and SBP with ertugliflozin 5\u2009and 15\u2009mg at week 26 were \u22120.9% and \u22121.0%, \u22121.9 and \u22121.8 kg, and \u22123.7 and \u22123.6\u2009mmHg, respectively; in participants aged 65\u2009years or older they were \u22120.6% and \u22120.8%, \u22121.9 and \u22122.2 kg, and \u22122.7 and \u22123.4\u2009mmHg, respectively. The incidences of AEs, serious AEs, discontinuations and deaths in participants aged less than 65\u2009years and those aged 65\u2009years or older were generally similar across the treatment groups. In patients aged 65\u2009years or older the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non\u2010ertugliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ertugliflozin improved glycaemic control, BW and SBP in younger and older individuals with T2D and was generally well tolerated in both groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14150","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T03:00:47Z","timestamp":1595473247000},"page":"2276-2286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase\n                    <scp>III<\/scp>\n                    studies"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-1389","authenticated-orcid":false,"given":"Richard","family":"Pratley","sequence":"first","affiliation":[{"name":"AdventHealth Translational Research Institute for Metabolism and Diabetes  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Dagogo\u2010Jack","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Charbonnel","sequence":"additional","affiliation":[{"name":"University of Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrita","family":"Patel","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Tarasenko","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annpey","family":"Pong","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misoo C.","family":"Ellison","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Huyck","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gantz","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-6193","authenticated-orcid":false,"given":"Steven G.","family":"Terra","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Andover Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00410108"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-37"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.07.011"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12670"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13124"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0573-0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2753"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12215"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-016-0382-1"},{"key":"e_1_2_10_16_1","unstructured":"Food and Drug Administration.STEGLATRO\u2122 (ertugliflozin). Prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209803s000lbl.pdf. Accessed October 10 2019."},{"key":"e_1_2_10_17_1","unstructured":"European Medicines Agency.STEGLATRO\u2122 summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/steglatro-epar-product-information_en.pdf. Accessed October 10 2019."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12888"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13103"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13194"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0354-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13116"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0337-5"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0358-0"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13251"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13631"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1583450"},{"issue":"1","key":"e_1_2_10_28_1","first-page":"S4","article-title":"Executive summary: standards of medical care in diabetes\u20102012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164119842513"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0856-7"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14028"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afz096"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0007"},{"key":"e_1_2_10_34_1","unstructured":"Janssen Pharmaceuticals I Titusville NJ 08560 USA. INVOKANA (canagliflozin) prescribing information.2018."},{"key":"e_1_2_10_35_1","unstructured":"Boehringer Ingelheim Pharmaceuticals I Ridgefield CT 06877 USA. JARDIANCE (empagliflozin) prescribing information.https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf. Accessed March 26 2020."},{"key":"e_1_2_10_36_1","unstructured":"AstraZeneca Pharmaceuticals LP W DE 19850 USA. FARXIGA (dapagliflozin) prescribing information.https:\/\/www.azpicentral.com\/farxiga\/farxiga.pdf. Accessed March 26 2020."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005473"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0849"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.08.016"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.14150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:40:33Z","timestamp":1761860433000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/dom.14150"],"URL":"https:\/\/doi.org\/10.1111\/dom.14150","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}